Peroxisome proliferator-activated receptor-α gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 7, 2011, Pages 1573-1579

  Lalloyer, Fanny ^a,b,c   Wouters, Kristiaan ^a,b,c   Baron, Morgane ^a,b,c   Caron, Sandrine ^a,b,c   Vallez, Emmanuelle ^a,b,c   Vanhoutte, Jonathan ^a,b,c   Baugé, Eric ^a,b,c   Shiri Sverdlov, Ronit ^d   Hofker, Marten ^e   Staels, Bart ^a,b,c   Tailleux, Anne ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; fatty liver disease; inflammation; murine model; PPAR

Indexed keywords

APOLIPOPROTEIN E2; FENOFIBRATE; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENE TARGETING; INFLAMMATION; LIPID METABOLISM; LIVER CELL; LIVER PROTECTION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; APOLIPOPROTEIN E2; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; FENOFIBRATE; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PPAR ALPHA;

EID: 79959696573     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.220525     Document Type: Article

References (34)

1. Staels B, Maes M, Zambon A. Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542-553.
2. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem. 1997;272: 27307-27312. (Pubitemid 27452695)
3. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003;38:123-132. (Pubitemid 36775803)
4. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39:1286-1296. (Pubitemid 38569050)
5. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol. 2006;44:732-741.
6. Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with peroxisome proliferation-activator receptor-α agonist Wy-14,643 protects murine fatty liver against ischemiareperfusion injury. Hepatology. 2010;51:996-1006.
7. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580. (Pubitemid 43326861)
8. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1897-1902. (Pubitemid 41243460)
9. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 2001;107:1025-1034. (Pubitemid 32323412)
10. Tordjman KM, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, Vechoropoulos M, Stern N. Absence of peroxisome proliferator-activated receptor-α abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension. 2007;50:945-951. (Pubitemid 350287539)
11. Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF. Macrophage expression of peroxisome proliferator-activated receptor-α reduces atherosclerosis in lowdensity lipoprotein receptor-deficient mice. Circulation. 2007;116: 1404-1412. (Pubitemid 47417567)
12. Fu T, Kashireddy P, Borensztajn J. The peroxisome-proliferator-activated receptor α agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem J. 2003;373:941-947. (Pubitemid 36981105)
13. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem. 2002;277: 48051-48057. (Pubitemid 35470751)
14. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem. 2006;285:35-50.
15. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012-3022.
16. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998; 102:130-135. (Pubitemid 28323839)
17. Mansouri RM, Bauge E, Staels B, Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-α control of the acute-phase response. Endocrinology. 2008;149:3215-3223. (Pubitemid 351724503)
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. (Pubitemid 17064313)
19. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
20. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 1999;96:7473-7478. (Pubitemid 29299686)
21. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489-1498.
22. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem. 2000;275:28918-28928.
23. Gervois P, PinedaTorra I, Chinetti G, Grotzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, Staels B. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol. 1999;13:1535-1549. (Pubitemid 30650594)
24. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia. 2000;43: 673-680. (Pubitemid 30322086)
25. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, Froguel P. Mutation screening of the PPARα gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab. 2000;26:393-401.
26. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007;50:1723-1731. (Pubitemid 47036647)
27. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200-205. (Pubitemid 351181792)
28. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006; 22:873-883. (Pubitemid 43875555)
29. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B. Characterization of the human PPARα promoter: identification of a functional nuclear receptor response element. Mol Endocrinol. 2002;16:1013-1028. (Pubitemid 34478538)
30. Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med. 2005;43:470-479. (Pubitemid 41460623)
31. Zhang SH, Reddick RL, Burkey B, Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 1994;94:937-945. (Pubitemid 24286433)
32. Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci. 2003;24:530-534. (Pubitemid 37244006)
33. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ. The human peroxisome proliferator-activated receptor α gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics. 2000;10:321-333. (Pubitemid 30345180)
34. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation. Arterioscler Thromb Vasc Biol. 2005;25:585-591. (Pubitemid 40315682)